Archive - February 2018
Brookdale rejects buyout offer, announces turnaround plan
Teva shutters New York, D.C. offices and dismisses lobbyists as part of U.S. consolidation drive
CMS looks to study MIPS burdens on clinicians
FiercePharmaAsia—More Takeda deals, China’s pharma supply issues, Merck KGaA expansion
Gilead signs $3bn-plus gene-editing deal with Sangamo
Guest Commentary: Data analytics hold promise in battle against opioid abuse
Priority review for Shire’s HAE drug
Novartis’ Ultibro Breezhaler reduces lung hyperinflation in COPD patients